ClinicalTrials.gg
RecruitingNCT06733376Updated Oct 28, 2026

Evaluating Evidenced Based Options for PTSD Treatment

An interventional study of Cognitive Processing Therapy and Prolonged Exposure in PTSD - Post Traumatic Stress Disorder, sponsored by Rush University Medical Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Rush University Medical Center · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
400
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 114 studies in Combat Disorders with a site in United States — 41 open to participants now, 44 under way, 2 of them phase 3. Combat Disorders · United States.

Planned enrollment
5th of 100
400 · median 74
Started
2025
with 21 others
No phase
72 of 114
26 open now
Primary completion
2029-06
later than 35 of 43 live
Registered
70th of 114
by date

Among the 114 studies in Combat Disorders with a site in United States, this one is the 5th largest by planned enrollment of the 100 interventional ones that give a count, is one of 22 that started in 2025, is one of 72 with no phase, reaches primary completion later than 35 of the 43 other live ones, and was the 70th registered.

Combat Disorders

204 studies on the registry are indexed under Combat Disorders; 93 are open to participants now.

Browse Combat Disorders studies →

Open to participants now

41 of the 114 studies in Combat Disorders with a site in United States are open now. Recruiting first, the newest first:

35 more — sign in →

All 41 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 53 Combat Disorders studies recruiting now, 22 (42%) set no upper age limit and 26 (49%) stop at 75 or younger; 10 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 114 studies in Combat Disorders with a site in United States, or all of them as a file.
02

Study summary

This study will look at:

How practical it is to offer another round of proven therapy. How effective different therapy options are for people who didn't respond to the first treatment.

The goal is to improve personalized care by:

Identifying factors that might predict how someone will respond to a second treatment.

Creating a simple tool to spot people who might not respond to treatment early, so they can start a different option sooner.

The findings will help improve PTSD care by offering better follow-up treatments and matching patients with the approach that works best for them.

03

Conditions studied

  • PTSD - Post Traumatic Stress Disorder

Browse trials for

Keywords

  • ptsd treatment
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Are 18 years or older
  • Are fluent in English
  • Have experienced a Criterion A traumatic event during their lifetime
  • Have a PTSD diagnosis verified via the Clinician Administered PTSD Scale for
  • Are interested in receiving evidence-based treatment for PTSD and able to attend 10 therapy sessions over the course of 2 weeks (10 days) and could possibly attend another 10 sessions of a subsequent treatment (additional CPT sessions, PE, or STAIR)
  • Are willing and able to complete self-report measures and clinician-rated assessments at multiple timepoints over the course of the study

Exclusion criteria

Exclusion Criteria:

  • The index traumatic event occurred in the past month
  • They are currently suicidal or homicidal (i.e., current plan and imminent intent)
  • They have unmanaged psychosis or mania
  • They have not been on a stable dose of psychotropic medication for at least one month at the time of the baseline assessment
  • They have completed an evidence-based cognitive behavioral PTSD treatment in the past three months or are currently engaged in an evidence-based PTSD treatment (CPT, PE)
  • They have an intellectual disability or significant cognitive impairment that would prevent them from engaging in treatment
  • They have a serious or unstable medical illness or instability for which hospitalization may be likely within the next year
  • They have an active substance use disorder (within the past three months) that would require immediate medical observation if substance was abruptly discontinued
  • They are involved with current legal actions related to their index trauma
  • They have a visual or auditory impairment that would prevent them from fully participating in study activities
  • They, at the time of consent, appear to have extenuating life circumstances (i.e., unstable housing, no internet access, etc.) which, in the judgement of the study team, could affect the ability to deliver interventions with fidelity
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
400 participants (estimated)

Study arms

  • Other
    Initial Course of Cognitive Processing Therapy

    All participants will start in Arm 1 where they receive 10-sessions of Cognitive Processing Therapy.

    Behavioral: Cognitive Processing Therapy

  • Active comparator
    Subsequent Treatment

    At one-week follow up after initial Cognitive Processing Therapy, participants whose scores are 28 or above on the PTSD Checklist for DSM-5 will be offered a subsequent course of treatment.

    Behavioral: Cognitive Processing Therapy · Behavioral: Prolonged Exposure · Behavioral: Skills Training for Affective and Interpersonal Regulation

Interventions

  • BehavioralCognitive Processing Therapy

    Cognitive Processing Therapy is a first-line intervention for the treatment of PTSD that focuses on changing unhelpful patterns of thinking.

    Also known as: CPT

  • BehavioralProlonged Exposure

    Prolonged Exposure is an evidence-based treatment for PTSD that helps to reduce the intensity of distress by gradually exposing participants to trauma-related memories, feelings, and situations in real life.

    Also known as: PE

  • BehavioralSkills Training for Affective and Interpersonal Regulation

    Skills Training for Affective and Interpersonal Regulation (STAIR) is a evidence-based treatment geared towards helping regulate emotional and interpersonal needs of those with PTSD.

    Also known as: STAIR

06

What researchers measure

Primary outcomes

  1. PTSD Checklist for DSM-5 (PCL-5)

    A self-report measure of PTSD symptom severity

    Time frame: Baseline to 6 month follow up

  2. Clinician Administered PTSD Scale for DSM-5

    A clinician-rated assessment of PTSD

    Time frame: Baseline to 6 mont follow up

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Held P, Hutzler I, Warren M, Streubel O, Pridgen SA, Smith DL, Cloitre M, Rothbaum BO, Kaysen DL. Evaluating evidence based options for initial PTSD treatment non-response: A randomized controlled trial protocol. Contemp Clin Trials Commun. 2026 Sep 15;54:101685. doi: 10.1016/j.conctc.2026.101685. eCollection 2026 Dec. PubMed 42780432 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Jun 2029, 43 months after the start.

Of 76 non-industry interventional studies with no phase under Combat Disorders, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 44. This study's planned 43 months is above that.

Counting every sponsor, half of 82 studies reached it within 25 months; a quarter within 12 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 10, 2024
First posted
Dec 13, 2024
StartActual
Oct 6, 2025
Primary completionEst.
Jun 1, 2029
CompletionEst.
Jun 1, 2030
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 42780432 ↗
Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 42780432 ↗
    + 2 other changes: verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06733376
Responsible party
Philip Held (Research Director, Rush University Medical Center) — Principal investigator
First posted
Dec 13, 2024
Start date
Oct 6, 2025
Primary completion
Jun 1, 2029 (estimated)
Completion
Jun 1, 2030 (estimated)
Last update
Oct 28, 2026

Study contacts

Philip Held, PhD
Contact
philip_held@rush.edu
312-942-1423
Sarah Pridgen, MA
Contact
sarah_pridgen@rush.edu
312-563-0577

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion